Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 15/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26658767 | 0.86 | TIPARP (0.44) | TIPARPTNKSPARP14PARP10PARP12 | |
| SCHEMBL25904508 | 0.86 | TIPARP (0.44) | TIPARPTNKSPARP14PARP10PARP12 | |
| SCHEMBL31058388 | 0.81 | TIPARP (0.40) | TIPARPROCK2ROCK1KITFLT3 | |
| SCHEMBL25904908 | 0.81 | TIPARP (0.44) | TIPARPTNKSPARP14PARP10PARP12 | |
| SCHEMBL25904910 | 0.81 | TIPARP (0.44) | TIPARPTNKSPARP14PARP10PARP12 | |
| SCHEMBL25904816 | 0.80 | TIPARP (0.42) | TIPARPTNKSPARP14PARP10PARP12 | |
| SCHEMBL25320275 | 0.80 | TIPARP (0.50) | TIPARPTNKSPARP14PARP10PARP12 | |
| SCHEMBL30550654 | 0.80 | TIPARP (0.50) | TIPARPTNKSPARP14PARP10PARP12 | |
| SCHEMBL25903730 | 0.80 | TIPARP (0.50) | TIPARPTNKSPARP14PARP10PARP12 | |
| SCHEMBL25903612 | 0.80 | TIPARP (0.50) | TIPARPTNKSPARP14PARP10PARP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | TIPARP 491/4885TNKS 19/4885PARP14 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.